Cargando…

Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib

BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...

Descripción completa

Detalles Bibliográficos
Autores principales: Pálmason, Róbert, Lindén, Ola, Richter, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498562/
https://www.ncbi.nlm.nih.gov/pubmed/26167286
http://dx.doi.org/10.1186/s12878-015-0029-1
_version_ 1782380640131350528
author Pálmason, Róbert
Lindén, Ola
Richter, Johan
author_facet Pálmason, Róbert
Lindén, Ola
Richter, Johan
author_sort Pálmason, Róbert
collection PubMed
description BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib. CASE PRESENTATION: We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated with Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative disorder in the CNS. CONCLUSIONS: Our report further underlines that patients treated with Ruxolitinib should be monitored closely for reactivations of opportunistic pathogens and viral infections.
format Online
Article
Text
id pubmed-4498562
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44985622015-07-11 Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib Pálmason, Róbert Lindén, Ola Richter, Johan BMC Hematol Case Report BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib. CASE PRESENTATION: We report a case of a 57 year old female with post-polycythemic myelofibrosis who was treated with Ruxolitinib. Approximately 9 weeks later she presented with a rapidly fatal, suspected EBV driven lymphoproliferative disorder in the CNS. CONCLUSIONS: Our report further underlines that patients treated with Ruxolitinib should be monitored closely for reactivations of opportunistic pathogens and viral infections. BioMed Central 2015-07-11 /pmc/articles/PMC4498562/ /pubmed/26167286 http://dx.doi.org/10.1186/s12878-015-0029-1 Text en © Pálmason et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Pálmason, Róbert
Lindén, Ola
Richter, Johan
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
title Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
title_full Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
title_fullStr Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
title_full_unstemmed Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
title_short Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
title_sort case-report: ebv driven lymphoproliferative disorder associated with ruxolitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498562/
https://www.ncbi.nlm.nih.gov/pubmed/26167286
http://dx.doi.org/10.1186/s12878-015-0029-1
work_keys_str_mv AT palmasonrobert casereportebvdrivenlymphoproliferativedisorderassociatedwithruxolitinib
AT lindenola casereportebvdrivenlymphoproliferativedisorderassociatedwithruxolitinib
AT richterjohan casereportebvdrivenlymphoproliferativedisorderassociatedwithruxolitinib